A Phase 2 interventional study of LY4086940 and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Not yet recruiting at 46 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 40th largest by planned enrollment of the 117 interventional ones that give a count, is one of 25 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 33 of the 53 other live ones, and was the 116th registered.
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
Browse Obesity studies →30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 460 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Median enrollment 267 across the 117 interventional studies. Of the 62 that completed or were terminated, 29 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
29 of the studies in Obesity by Eli Lilly and Company that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06662383Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | 2026-11 |
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07232719Phase 3Eli Lilly and CompanyA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | 2027-06 |
Add all 29 to your calendar (.ics) → With an account.
Among the 118 studies in Obesity by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.
Participation in the study will last about 58 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition to exclusion criteria under Master Protocol CWMM (NCT06143956)
Have any of the following cardiovascular conditions within 6 months prior to screening:
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive LY4086940 orally
Drug: LY4086940
Participants will receive placebo orally
Drug: Placebo
Administered orally
Administered orally
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 32
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 48
Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)
Time frame: Baseline, Week 32, Week 48
Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State
Time frame: Week 48
PK: Maximum Concentration (Cmax) of LY4086940 at Steady State
Time frame: Week 48
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Start is estimated for Nov 2026; primary completion for Jan 2028, 14 months later.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 14 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.